Divis Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xkqaq82rrxbtitjdhf581vlb.pdf

Key Takeaways


Custom Synthesis: The Mix Shift in Motion

Dr. Kiran S. Divi: "During that process, we bring the most effective route, we discuss with the innovator in hand, and then we work with them in re-qualifying this new process which is more cost effective and helping them to keep the market share."

Generic Business: Pricing Pressure and Market Share

Dr. Kiran S. Divi: "The generic business, in general, we have not lost any market share. In fact, we have gained market share in several of our large-volume APIs."

Contrast Media & GLP-1: The 2025 Opportunity

Dr. Kiran S. Divi: "We start our chemistry right from Iodine. We know the art of recovering Iodine thereby bring our costs down. And that's why we are efficient in atom-to-atom efficiency. So, price-wise, cost-wise, and quality, we are much more superior in the generic market and that's where a lot of people are qualifying and moving."

Kakinada: The Capacity Catalyst


Margins, Costs & Headwinds


Nutraceuticals & Other Businesses


Guidance & Commitments

CommitmentSpecificsTimeline
Generic pricing stabilityCompetitor destocking cycle ends, pricing stabilizesNext 2-3 quarters
Kakinada production startProduction activity begins at greenfield siteEnd of Q2 FY25
Kakinada commercializationCommercial production begins, subject to regulatory approvalsEnd of Q3 FY25
Revenue growthDouble-digit year-on-year growth with Kakinada contributionFY25
GLP-1/contrast media contribution"Good numbers" and "positive results" from both frontsFrom 2025
Patent expiry productsOne or two patents expire, products begin commercializing2025, with more in 2026-2028
Custom synthesis contributionFurther increase from two major projects as volumes scaleComing quarters

Key Metrics

MetricQ3 FY24
Consolidated total income₹1,950 cr, vs ₹1,821 cr in Q3 FY23 and ₹1,995 cr in Q2 FY24
Profit before tax₹489 cr
Profit after tax₹358 cr
Material consumption39% of revenue, down due to favorable product mix and softening raw material prices
Forex gain₹18 cr, vs ₹47 cr in Q3 FY23
Constant currency growth (quarter)7%
Constant currency growth (9 months)negative 10%
Exports share~87% of revenue; exports to Europe and America at ~71%
Product mix (generics to custom synthesis)54% to 46%, vs 60% to 40% in Q2 FY24
Nutraceutical business revenue₹153 cr
Capacity utilization~80%
Kakinada investment during FY24₹458 cr, 7 production blocks built
Market share gain in large-volume generic products3% to 5%
Nutraceutical business growth~10% steady growth year on year
GLP-1 dedicated capacityseveral hundreds of tonnes